NCT07387198
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07387198
Title Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab (NeoMatryx)
Acronym NeoMatryx
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications
Therapies
Age Groups: senior | adult
Covered Countries DEU


No variant requirements are available.